BBR	NNP
2778	CD
was	VBD
synthesized	VBN
and	CC
initially	RB
characterized	VBN
in	IN
vitro	NN
for	IN
tumor	NN
cell	NN
cytotoxicity	NN
and	CC
mechanism	NN
of	IN
action	NN
by	IN
studies	NNS
at	IN
the	DT
Boehringer	NNP
Mannheim	NNP
Italia	NNP
Research	NNP
Center	NNP
,	,
Monza	NNP
,	,
and	CC
University	NNP
of	IN
Vermont	NNP
,	,
Burlington	NNP
.	.

Other	JJ
studies	NNS
have	VBP
been	VBN
completed	VBN
at	IN
the	DT
University	NNP
of	IN
Texas	NNP
M.	NNP
D.	NNP
Anderson	NNP
Cancer	NNP
Center	NNP
,	,
Houston	NNP
,	,
the	DT
Istituto	NNP
Nazionale	NNP
Tumori	NNP
,	,
Milan	NNP
,	,
and	CC
the	DT
University	NNP
of	IN
Padua	NNP
.	.

In	IN
the	DT
search	NN
for	IN
novel	NN
heteroanalogs	NNS
of	IN
anthracenediones	NNS
,	,
it	PRP
was	VBD
selected	VBN
as	IN
the	DT
most	RBS
promising	JJ
compound	NN
.	.

Toxicological	JJ
studies	NNS
indicated	VBD
that	IN
BBR	NNP
2778	CD
was	VBD
not	RB
cardiotoxic	JJ
,	,
and	CC
US	NNP
patents	NNS
are	VBP
held	VBN
by	IN
the	DT
University	NNP
of	IN
Vermont	NNP
.	.

